4.7 Article

Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease

期刊

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.954

关键词

-

资金

  1. INSERM
  2. CNAMTS
  3. Lilly
  4. Novartis Pharma
  5. Sanofi-Aventis
  6. Association Diabete Risque Vasculaire
  7. Federation Francaise de Cardiologie
  8. La Fondation de France
  9. ALFEDIAM
  10. ONIVINS
  11. Ardix Medical
  12. Bayer Diagnostics
  13. Becton Dickinson
  14. Cardionics
  15. Merck Sante
  16. Novo Nordisk
  17. Pierre Fabre
  18. Roche
  19. Topcon
  20. European Union [EURODIA LSHM-CT-2006-518153]
  21. GlaxoSmithKline
  22. Deutsche Forschungsgemeinschaft
  23. Deutsche Herzstiftung
  24. National Genome Research Network 2 of the German Federal Ministry of Education and Research
  25. Canadian Institutes of Health Research
  26. Heart and Stroke Foundation of Ontario
  27. International Clinical Epidemiology Network (INCLEN)
  28. Chile, Universidad de la Frontera, Sociedad Chilena de Cardiologia Filial Sur
  29. Colombia, Colciencias, Ministerio de Salud
  30. Croatia, CroatianMinistry of Science and Technology
  31. Guatemala, Liga Guatemalteca del Corazon
  32. Hungary, Astra Hassle, National Health Science Council, George Gabor Foundation
  33. Iran, Iran Ministry of Health
  34. Italy, Boehringer-Ingelheim
  35. Japan, Sankyo Pharmaceutical Co
  36. Banyu Pharmaceutical Co, Astra Japan
  37. Kuwait, Endowment Fund for Health Development in Kuwait
  38. Pakistan, ATCO Laboratories
  39. Philippines, Philippine Council for Health Research and Development
  40. Pfizer Philippines Foundation, Inc
  41. Astra Pharmaceuticals Inc
  42. Astra Fund for Clinical Research and Continuing Medical Education
  43. Pharmacia and Upjohn Inc
  44. Poland, Foundation PROCLINICA
  45. Singapore, Singapore National Heart Association
  46. South Africa, Medical Research Council of South Africa
  47. Warner-Parke-Davis Pharmaceuticals
  48. Aventis
  49. Swedish State under the LUA agreement
  50. Swedish Heart and Lung Foundation
  51. Thailand, Heart Association of Thailand
  52. Thailand Research Fund
  53. British Heart Foundation
  54. Medical Research Council
  55. Cancer Research UK
  56. Tobacco Products Research Trust
  57. Giorgi-Cavaglieri Foundation
  58. Swiss National Science Foundation [3100AO-116323/1]
  59. Universite de Lausanne, Lausanne, Switzerland.
  60. British Heart Foundation [SP/04/002]
  61. National Heart, Lung, and Blood Institute [5R01HL087679-02]
  62. Medical Research Council of the United Kingdom
  63. European Birth Life-Course Study
  64. European Commission [QLG1-CT2000-01643]
  65. Biocenter Oulu of University of Oulu
  66. Academy of Finland
  67. National Institute of Mental Health [1RL1MH083268-01]
  68. EC Sixth Framework Programme [LSHM33 CT-2007-037273]
  69. Wellcome Trust
  70. MRC [G0700931, G0600331, G0601966, G0801056, MC_U137686857] Funding Source: UKRI
  71. Medical Research Council [G0600331, G0700931, MC_U137686857, G0801056, G0601966, G0801056B] Funding Source: researchfish

向作者/读者索取更多资源

Context Plasma levels of C-reactive protein (CRP) are independently associated with risk of coronary heart disease, but whether CRP is causally associated with coronary heart disease or merely a marker of underlying atherosclerosis is uncertain. Objective To investigate association of genetic loci with CRP levels and risk of coronary heart disease. Design, Setting, and Participants We first carried out a genome-wide association (n = 17 967) and replication study (n = 13 615) to identify genetic loci associated with plasma CRP concentrations. Data collection took place between 1989 and 2008 and genotyping between 2003 and 2008. We carried out a mendelian randomization study of the most closely associated single-nucleotide polymorphism (SNP) in the CRP locus and published data on other CRP variants involving a total of 28 112 cases and 100 823 controls, to investigate the association of CRP variants with coronary heart disease. We compared our finding with that predicted from meta-analysis of observational studies of CRP levels and risk of coronary heart disease. For the other loci associated with CRP levels, we selected the most closely associated SNP for testing against coronary heart disease among 14 365 cases and 32 069 controls. Main Outcome Measure Risk of coronary heart disease. Results Polymorphisms in 5 genetic loci were strongly associated with CRP levels (% difference per minor allele): SNP rs6700896 in LEPR (-14.8%; 95% confidence interval [CI], -17.6% to -12.0%; P = 6.2 x 10(-22)), rs4537545 in IL6R (-11.5%; 95% CI, -14.4% to -8.5%; P = 1.3 x 10(-12)), rs7553007 in the CRP locus (-20.7%; 95% CI, -23.4% to -17.9%; P = 1.3 x 10(-38)), rs1183910 in HNF1A (-13.8%; 95% CI, -16.6% to -10.9%; P = 1.9 x 10(-18)), and rs4420638 in APOE-CI-CII (-21.8%; 95% CI, -25.3% to -18.1%; P = 8.1 x 10(-26)). Association of SNP rs7553007 in the CRP locus with coronary heart disease gave an odds ratio (OR) of 0.98 (95% CI, 0.94 to 1.01) per 20% lower CRP level. Our mendelian randomization study of variants in the CRP locus showed no association with coronary heart disease: OR, 1.00; 95% CI, 0.97 to 1.02; per 20% lower CRP level, compared with OR, 0.94; 95% CI, 0.94 to 0.95; predicted from meta-analysis of the observational studies of CRP levels and coronary heart disease (z score, -3.45; P < .001). SNPs rs6700896 in LEPR (OR, 1.06; 95% CI, 1.02 to 1.09; per minor allele), rs4537545 in IL6R (OR, 0.94; 95% CI, 0.91 to 0.97), and rs4420638 in the APOE-CI-CII cluster (OR, 1.16; 95% CI, 1.12 to 1.21) were all associated with risk of coronary heart disease. Conclusion The lack of concordance between the effect on coronary heart disease risk of CRP genotypes and CRP levels argues against a causal association of CRP with coronary heart disease. JAMA. 2009;302(1):37-48

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据